Kamada Stock

Kamada Dividend

The Dividend of Kamada (KMDA) as of Aug 6, 2026 is 0.20 USD.

Dividend

0.20USD

Dividend yield

0.01 %

Last updated:

How much dividend does Kamada 2026 pay?

According to the latest status from August 2026, Kamada paid a total of 0.20 USD per share in dividends within the last 12 months. With the current Kamada price of 2,115.00 USD, this corresponds to a dividend yield of 0.01 %. A dividend is paid times per year.

Kamada currently offers a dividend yield of about 0.01%. The payout ratio is around 61% of earnings.

Historical Kamada Dividends

A dividend is paid times per year. Last year, the payout months were and April.

PaydateDividend
4/23/20260.25USD
4/17/20250.20USD

Kamada dividend history and estimates

In 2025, Kamada paid a dividend amounting to 0.20 USD. Dividend means that Kamada distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2025
0.20 USD
0.00 USD
Jan 1, 2026
0.25 USD
0.00 USD
Jan 1, 2027 (e)
0.00 USD
0.30 USD

Is the Kamada Dividend Safe?

Kamada has been increasing the dividend for 0 years.

Analysts expect a Dividend Increase of 11.80% for the current fiscal year.

Kamada dividend payout ratio

In 2025, Kamada had a payout ratio of 61.06%. The payout ratio indicates the percentage of the company's profits that Kamada distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
61.06 %
Jan 1, 2021
61.06 %
Jan 1, 2022
61.06 %
Jan 1, 2023
61.06 %
Jan 1, 2024
61.06 %
Jan 1, 2025
61.06 %
Jan 1, 2026 (e)
58.48 %
Jan 1, 2027 (e)
48.92 %

Dividend Details

Understanding Kamada's Dividend Distributions

Kamada’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Kamada's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Kamada's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Kamada’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Kamada Stock analysis

What does Kamada do? Kamada Ltd is an Israel-based company specializing in the development and marketing of biopharmaceutical products for humans and animals. The company was founded in 1990 by a team of experienced executives and scientists from the biotech industry. Since its inception, Kamada has become a global leader in plasma fractionation and the production of antibodies and enzymes. The company is listed on the NASDAQ and the Tel Aviv Stock Exchange and has over 450 employees in its facilities in Israel and the USA. Kamada's business model is based on combining innovative science and technology to develop products and therapies for rare and severe diseases. The company is constantly working to improve its production processes to deliver more efficient and cost-effective products. Kamada operates in three divisions: human therapeutics, veterinary medicine, and plasma research. The human therapeutics division develops and markets products for the treatment of diseases such as alpha-1 antitrypsin deficiency, immunoglobulin deficiency, hemophilia, and other serious conditions. The veterinary medicine division offers products for the treatment of diseases in dogs, horses, and cows to veterinary professionals. The plasma research division focuses on developing technologies for the production of plasma derivatives and discovering new applications for plasma proteins. Kamada has a wide range of products on the market, including its flagship product Glassia, which is used to treat alpha-1 antitrypsin deficiency, a rare genetic disease that can affect the lungs. The company also produces intravenous immunoglobulin preparations for the treatment of immune deficiencies and other immune system disorders, as well as recombinant factor VIII for the treatment of hemophilia. In veterinary medicine, Kamada offers products such as Equine Seramune, designed for horses and used to treat life-threatening infections caused by bacteria found in the intestines of horses. The company also produces products for the treatment of mastitis, an infection of the milk ducts in cows, and gastrointestinal tract infections in dogs. Kamada takes pride in playing a leading role in plasma research and technology. The company's research has resulted in groundbreaking technologies that allow for the faster and more cost-effective production of important plasma proteins than was previously possible. Kamada works closely with other research institutions and companies to collaborate on solutions for severe and rare diseases. Over the years, Kamada has received numerous awards and recognition for its groundbreaking research and development work. The company is committed to continuing to develop innovative products and therapies to improve the lives of patients with rare and severe diseases. Overall, Kamada Ltd has experienced remarkable growth in recent years. It is a company that plays a leading role in the market for biopharmaceutical products based on top-notch scientific research and efficient technology. In the future, Kamada will undoubtedly continue to develop groundbreaking products and therapies to improve the lives of patients worldwide. Kamada is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kamada stock

Over the past 12 months, Kamada paid a dividend of 0.20 USD . This corresponds to a dividend yield of about 0.01 %. For the coming 12 months, Kamada is expected to pay a dividend of 0.30 USD.

The current dividend yield of Kamada is 0.01 %.

Kamada paid dividends every year for the past 1 years.

For the upcoming 12 months, dividends amounting to 0.30 USD are expected. This corresponds to a dividend yield of 0.01 %.

Kamada is assigned to the 'Health' sector.

To receive the latest dividend of Kamada from amounting to 0.25 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Kamada are distributed in USD.

Dividend calendar 2026
Access this data via the Eulerpool API
Get Free API Key

All Key Metrics — Kamada